G1 Therapeutics, Inc.
700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709
United States
919 213 9835
https://www.g1therapeutics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 100
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. John E. Bailey Jr. | CEO, President & Director | 1.19M | 無 | 1965 |
| Dr. Rajesh K. Malik Ch.B., M.B., M.D. | Chief Medical Officer | 653.56k | 無 | 1959 |
| Mr. Mark Avagliano | Chief Business Officer | 663.73k | 無 | 1976 |
| Mr. John W. Umstead V | Chief Financial Officer | 無 | 無 | 1985 |
| Mr. Terry L. Murdock MSc | Chief Operating Officer | 541.59k | 606.34k | 1960 |
| Mr. William C. Roberts | Vice President of Investor Relations & Corporate Communications | 無 | 無 | 1969 |
| Ms. Monica Roberts Thomas | Chief Legal & People Officer | 無 | 無 | 無 |
| Mr. Evan Hicks M.B.A. | Vice President of Marketing | 無 | 無 | 無 |
| Mr. Andrew Perry | Chief Commercial Officer | 568.6k | 無 | 1974 |
| Mr. Jeff Macdonald | Senior Director of Investor Relations & Corporate Communications | 無 | 無 | 無 |
描述
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
公司管治
截至 2024年5月1日 止，G1 Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：4；董事會：7；股東權利：8；現金賠償：9。
